strong oper perform ms sma biosimilar franchis
maintain buy rate downgrad tp
provid upsid potenti
estim adjust ep
forward price-to-earnings multipl
estim base follow factor strong
growth ms sma biosimilar product acquisit
nightstar discontinu alzheim drug
deliv strong financi result quarter
due strong oper perform ms sma
biosimilar franchis total revenu increas
adjust ep increas
howev eisai co ltd announc decis
discontinu global phase trial engag
emerg design evalu efficaci safeti
aducanumab patient alzheim diseas led
huge dip stock price quarter
therefor downgrad tp
base price-to-earnings multipl expect slow
growth rate
announc enter share purchas
agreement fujifilm corpor fujifilm
fujifilm acquir share subsidiari
hold biolog manufactur oper hillerd
denmark cash subject minimum
purchas commit guarante contractu
compani name inctickerbiibstock ratingbuyunchangedindustri viewoverweightpositivepric june week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc| june
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
announc enter agreement
acquir nightstar therapeut clinical-stag gene
therapi compani base london unit kingdom
pay cash nst share focus
adeno-associ viru aav treatment inherit
multipl sclerosi ms revenu includ
royalti sale ocrevu rel stabl
revenu growth driven
part continu global launch spinraza
spinraza revenu increas
sale sale outsid
 number commerci patient receiv
spinraza grew outsid
biosimilar revenu increas due
launch imraldi revenu increas
due sale
remain hemophilia inventori hand bioverativ inc
current price-to-earnings multipl
averag price-to-earnings stock price dip
quarter due failur drug price-to-earnings trail
till februari expect forward price-to-earnings multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend rate n/a forward annual dividend yield n/a trail annual dividend rate n/a trail annual dividend yield n/a year averag dividend yield n/a pay-out dividend date n/a ex-dividend date n/a last split factor new per last split date jan inform biogen inc| june
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research develop sell gener administr sg incom expens oper interest incom special interest minor incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli inc| june
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom non-curr assets- total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in capital- retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item biogen inc| june
net cash flow provid oper activ increas compar
due higher net incom off-set chang asset liabil
net cash flow use invest activ declin compar
due decreas net proce relat market secur partial
off-set decreas conting payment made former sharehold fumapharm ag
holder right
net cash use financ activ increas compar
due increas cash use share repurchas
depreciation- defer incom oper increas decreas increas decreas current decreas increas payables- decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment dividends- financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc| june
report solid revenu growth year led continu strong
global penetr spinraza signific gain biosimilar busi
resili core ms busi
compar
total revenu increas compar
total product revenu increas
compar increas due
increas revenu spinraza increas revenu
biosimilar product
sale increas
compar
total revenu therapeut program increas
compar increas
due increas net sale rituxan
increas royalti revenu sale ocrevu
revenu increas compar
increas due sale hemophilia relat
inventori bioverativ inc bioverativ total quarter
sale increas compar
product cost sale increas
compar increas product cost
sale due higher contract manufactur shipment result
sale hemophilia relat inventori bioverativ cost basi total
pursuant term manufactur suppli agreement
bioverativ enter connect spin-off hemophilia
busi increas sale biosimilar product
royalti cost sale increas
compar increas royalti cost sale
due increas royalti payabl ioni higher sale spinraza
partial off-set decreas royalti payabl sale tysabri result
expir certain third parti royalti
 expens increas compar
increas due increas mileston
up-front expens increas cost incur connect
earli late stage program increas partial off-set
decreas cost incur market product research
research discoveri
mileston up-front expens
increas mileston up-front expens due recognit
charg expens upon enter collabor
research develop servic agreement skyhawk
increas spend relat earli stage program due
develop -synuclein mab parkinson diseas
develop mab ad pursuant collabor
arrang eisai develop ampa cia
increas partial off-set decreas cost associ
develop vixotrigin trigemin neuralgia
develop glibenclamid iv larg hemispher infarct
lhi advanc late stage program
increas spend relat late stage program due cost
incur result discontinu phase aducanumab trial
net expect eisai reimburs develop
increas
compar
increas mileston
up-front expens
due recognit
charg
collabor
servic agreement
compar
amort acquir
decreas
compar
decreas spend relat market product due
decreas spend zinbryta subsequ voluntari world-wide
withdraw zinbryta rm announc march
sg expens increas compar
non-gaap sg expens increas
compar increas due
increas corpor give increas commerci cost biogen
continu expand new intern market increas pre-
commerci cost relat ad program increas
partial off-set decreas oper spend zinbryta subsequ
voluntari world-wide withdraw zinbryta rm
announc march
loss asset liabil held sale
record loss condens consolid
statement incom estim loss includ pre-tax loss
reflect current estim fair valu asset liabil held
sale adjust expect cost sell hillerd denmark
manufactur oper estim fair valu
advers commit associ guarante futur
minimum batch product hillerd facil
amort acquir intang asset decreas
compar collabor profit share
compar gain fair valu
remeasur conting consider
restructur charg compar
oper incom decreas compar
incom includ net
gain invest driven increas fair
valu equiti invest non-gaap
expens
effect tax rate compar
increas due tax expens relat
propos divestitur subsidiari own hillerd denmark
manufactur oper effect non-gaap tax rate
compar
net incom increas compar
non-gaap net incom increas
compar
gaap ep increas
compar
increas
compar
gaap ep increas compar
non-gaap ep increas compar
book pre-tax loss relat share
purchas agreement fujifilm corpor fujifilm
fujifilm acquir outstand share subsidiari
own biolog manufactur oper hillerd denmark
repurchas share compani common stock total
valu april april
repurchas addit share common stock
cost
biogen board director author program repurchas
common stock addit remain
april share repurchas program author august
march cash cash equival market
secur total note payabl
gener net cash flow oper
weight averag dilut share
total product revenu increas
compar total product revenu
declin compar
total product revenu rest world increas
compar
increas
compar
tecfidera revenu
increas
compar
increas
compar
tecfidera revenu increas
compar anticip increas
tecfidera demand global basi expect volum growth
intern market exceed volum declin also
expect price reduct certain european countri
total revenu decreas
compar due decreas unit sale
volum higher discount allow
total revenu rest world increas
compar due increas unit
sale volum relat european latin american
decreas
compar
interferon revenu decreas
compar expect interferon
revenu continu declin intern
market result increas competit ms product
well treatment ms includ biosimilar price
reduct certain european market
total revenu decreas
compar due decreas
interferon unit sale volum attribut patient
transit ms therapi
total revenu rest world decreas
compar due price
reduct certain european market
decreas
compar
 decreas
compar
tysabri revenu
compar
tysabri revenu decreas compar
anticip tysabri demand stabl
global basi expect volum declin due increas
competit addit treatment ms includ ocrevu
off-set volum growth intern market
total revenu decreas
compar due decreas unit sale
volum partial off-set price increas lower discount
total revenu rest world increas
compar due
increas unit sale volum
decreas
compar
tysabri revenu
rest world
increas
compar
spinraza revenu
increas
compar
spinraza revenu increas
compar expect rate
spinraza revenu grow moder due lower
rate new patient start combin impact load dose
dynam patient transit dose everi four month
total revenu increas
compar due increas unit sale
volum
total revenu rest world increas
compar due
increas unit sale volum partial off-set unfavor
impact foreign currenc exchang
increas
compar
spinraza revenu
 increas
compar
benepali flixabi imraldi
increas
compar
biosimilar revenu
compar
increas
compar
biosimilar revenu increas
compar increas due launch
imraldi partial off-set unfavor impact
foreign currenc exchang expect strong revenu
growth biosimilar busi driven continu launch imraldi
benepali revenu increas
compar flixabi revenu increas
compar imraldi
revenu
revenu program
rituxan gazyva collabor oper profit
revenu therapeut program
revenu
therapeut program
compar
share pre-tax profit rituxan gazyva
compar
total product revenu increas
compar
increas product revenu due
increas net sale rituxan increas
net sale rituxan reflect sell price increas
increas unit sale volum increas also reflect
increas gazyva unit sale volum
share pre-tax
profit
rituxan gazyva
compar
increas product
revenu
due increas
net sale rituxan
opicinumab anti-lingo oral diroximel fumar elenbecestat anti-tau anti-tau mab ionis-maptrx anti-tau -synuclein mab f/k/a sma vixotrigin trigemin vixotrigin small fiber neuropath painneurocognit disordersbiib ampa glibenclamid iv lhi acut ischem stroke natalizumab epilepsydapirolizumab pegol slecor growth areasm neuroimmunologyalzheim diseaseand dementiaparkinson diseas movement disordersneuromuscular diseas includ sma alsemerg growth areaspainacut neurologytherapeut adjacenciesphas phase phase phase phase phase phase phase phase phase phase phase phase file phase phase phase phase phase phase phase phase phase inc| june
april present data rapidli progress natur
spinal muscular atrophi sma benefit treatment spinraza
muscular dystrophi associ mda clinic scientif
confer orlando florida present includ data
sever diseas progress adult adolesc older children
well data nurtur studi highlight benefit pre-
symptomat treatment find role neurofila
potenti biomark predict motor function sma
march first patient dose phase valor studi
tofersen antisens oligonucleotid amyotroph later
sclerosi al superoxid dismutas mutat valor
continu phase singl multiple-ascend dose studi
design assess efficaci safeti versu placebo
primari endpoint studi analysi base amyotroph
later sclerosi function rate scale-revis alsfrs-r score
collabor regul defin scope clinic data
packag requir support registr
march eisai co ltd announc decis
discontinu global phase studi engag emerg design
evalu efficaci safeti aducanumab patient mild
cognit impair due alzheim diseas mild alzheim
diseas dementia decis stop studi base result
futil analysi conduct independ data monitor committe
indic studi unlik meet primari endpoint
upon complet recommend stop studi base
safeti concern also decid initi phase secondari
prevent studi evalu whether earli use aducanumab prevent
delay clinic onset alzheim diseas time
march
decis discontinu
global phase studi
engag emerg
design evalu
efficaci safeti
aducanumab patient
mild cognit
impair due
alzheim diseas
announc
enter
agreement acquir
focus adeno-
treatment inherit
march announc enter share purchas
agreement fujifilm fujifilm acquir
outstand share subsidiari own biolog
manufactur oper hillerd denmark cash
subject work capit adjust contractu term
follow complet propos transact fujifilm would use
hillerd facil produc commerci product
tysabri well third-parti product propos transact
remain subject customari close condit includ file
clearanc danish competit act close propos
transact expect occur oper
manufactur facil research triangl park north carolina
solothurn switzerland expect oper end
march announc enter agreement
compani focus adeno-associ viru treatment inherit retin
disord term propos acquisit would pay
nst sharehold cash issu outstand nst share
offer repres total transact valu fulli dilut
basi take account expect transact expens anticip
cash acquir close
nst two potenti first-in-class mid- late-stag clinic asset well
preclin program nst lead asset phase develop
choroideremia rare degen disord lead blind
approv treatment option propos acquisit nst plan
fund avail cash account acquisit
busi close propos acquisit remain subject
customari close condit includ approv nst sharehold
issuanc order court expect complet
acquisit mid-year
februari announc spinraza approv
china nation medic product associ treatment sma
expand compani presenc china sma case
sma make common form diseas spinraza first
approv treatment china sma spinraza initi avail
china self-pay patient compani work secur provinci
februari plc announc food
drug administr fda accept review new drug
applic nda diroximel fumar novel oral fumar
develop treatment relaps form ms
approv intend market diroximel fumar brand
name vumer condit accept fda
confirm upon approv nda assign pdufa
prescript drug user fee act target action date fourth quarter
plc
announc
fda accept
review new drug
applic nda
rang
non-
ep
rang
financi result
quarter due strong
ms sma
expect revenu rang
expect ep rang
non-gaap ep rang
tax rate expect rang
capit expenditur expect
deliv strong financi result quarter due strong
oper perform ms sma biosimilar franchis total
revenu increas
multipl sclerosi ms revenu includ royalti sale
ocrevu rel stabl revenu
growth driven part continu global launch spinraza
contribut revenu
biosimilar revenu increas due launch
imraldi revenu increas due sale
remain hemophilia inventori hand bioverativ inc
gaap ep increas non-gaap ep increas
channel inventori level
decreas tecfidera avonex plegridi tysabri
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
gross margin ttm basi compar
net margin improv ttm basi compar
ep growth ttm basi compar
revenu growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc| june
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale biogen inc| june
invest flow
mrqfinanci mrqyoy growth revenu growthoper incom growthep mrqreturn mrqreturn mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth yoy biogen inc| june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item biogen inc| june
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc dividends- net chang capit free inc| june
current price-to-earnings multipl averag price-to-earnings stock price dip
quarter due failur drug price-to-earnings trail
till februari expect forward price-to-earnings multipl
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock vanguard group inc primecap manag clearbridg invest wellington manag compani capit world aqr capit manag geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard/primecap vanguard total stock market vanguard vanguard specialized-health legg mason clearbridg aggress growth vanguard horizon fund-capit opportun spdr etf vanguard institut fund-institut ishar nasdaq biotechnolog etf tr- qqq tr seri competit
developmentsbiogen spinraza nusinersen receiv posit recommend fund unit kingdom treatment infant children adult spinal muscular atrophymay announc nation institut excel unit kingdom recommend fund spinraza nusinersen nation servic nh posit recommend treatment infant children adult spinal muscular atrophi sma includ pre-symptomat symptomat sma type sma rare debilit life-threaten diseas result sever progress muscular atrophi weak data publish neurolog show treatment spinraza nusinersen improv motor function provid long-term benefit individu later-onset spinal muscular atrophyapril announc data open-label studi safeti toler spinraza individu later-onset spinal muscular atrophi sma publish peer-review journalneurolog medic journal american academi neurolog data show individu later-onset sma treat spinraza regain motor function previous lost treatment stabil diseas activ lead improv activ daili live biogen enter agreement sell large-scal biolog manufactur hillerd denmark fujifilmmarch announc enter share purchas agreement fujifilm corpor fujifilm fujifilm acquir share subsidiari hold biolog manufactur oper hillerd denmark cash subject minimum purchas commit guarante contractu term employe hillerd subsidiari expect continu employ fujifilm ownership biogen announc agreement acquir nightstar establish clinic pipelin gene therapi candid ophthalmologymarch announc enter agreement acquir nightstar therapeut clinical-stag gene therapi compani base london unit kingdom focus adeno-associ viru aav treatment inherit retin disord term propos acquisit pay cash nst share offer repres total transact valu fulli dilut basi take account expect transact expens anticip cash close inc| june
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
ytd stock perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc| june
consensu view analyst trend stock
low
compar
average
forward price-to-earnings
average
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonbiibindustri avg avgprice/earn yield inc| june
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr biogen inc| june
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
stock price dip march eisai discontinu phase engag
emerg trial aducanumab alzheim diseas
stock price volatil drug failur declin
stock price volatil till march show huge dip drug failur march
stock price declin past rang stock
stock price show huge fluctuat past stock declin past
stock surg septemb declin may
crispidea price target downgrad due huge declin stock price due
drug failur recommend buy rate stock base strong oper perform
ms sma biosimilar franchis quarter
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
